OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes related to inadequate glucocorticoid (GC) replacement. We compared disease control of adults with classic CAH treated with a modified release hydrocortisone (MRHC), which...

Descripción completa

Detalles Bibliográficos
Autores principales: Merke, Deborah P, Mallappa, Ashwini, Arlt, Wiebke, de la Perriere, Aude Brac, Hirschberg, Angelica Linden, Juul, Anders, Newell-Price, John D C, Perry, Colin Graham, Prete, Alessandro, Rees, Aled, Reisch, Nicole, Stikkelbroeck, Monica, Touraine, Philippe A, Maltby, Kerry, Treasure, Peter, Porter, John, Ross, Richard John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209435/
http://dx.doi.org/10.1210/jendso/bvaa046.214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209435/
http://dx.doi.org/10.1210/jendso/bvaa046.214

Ejemplares similares